GlassScriptPhysician profile
Christina Clarke
NPI 1972947059
$4,395.77
in general payments reported to CMS, 2019-2025
22 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $77.15 · 2021: $75.77 · 2022: $150 · 2023: $1,124 · 2024: $1,603 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,677 · Education: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,676.51 |
| Education | $416.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $676.67 | 2020-2025 | |
| Janssen Biotech, INC. | $473.32 | 2020-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $444.42 | 2022-2025 | Dupixent, Libtayo |
| Organon LLC | $336.64 | 2025 | Vtama |
| Dermavant Sciences, INC. | $314.90 | 2023-2024 | Vtama |
| Pfizer INC. | $308.03 | 2023-2025 | |
| Incyte Corporation | $257.96 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $219.76 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.18 | 2023-2024 | Spevigo, Cyltezo |
| Novartis Pharmaceuticals Corporation | $166.32 | 2023-2025 | |
| Ucb, INC. | $164.21 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $156.80 | 2023-2025 | Ilumya, Odomzo, Blu-U |
| Genzyme Corporation | $143.62 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $117.45 | 2022-2023 | Sotyktu |
| Leo Pharma INC. | $102.94 | 2022-2024 | Adbry |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strata Skin Sciences, INC. | $77.50 | 2023 | Xtrac |
| Amgen INC. | $63.69 | 2021-2024 | Otezla |
| Galderma Laboratories, L.P. | $55.34 | 2024-2025 | Oracea, Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.29 | 2024-2025 | Siliq, Cabtreo |
| Mallinckrodt Hospital Products INC. | $27.96 | 2024 | Acthar |
| Almirall LLC | $22.74 | 2025 | Klisyri |
| Biofrontera INC. | $18.03 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.